WATERTOWN, Mass., Sept. 6 /PRNewswire-FirstCall/ -- Panacos
Pharmaceuticals, Inc. (Nasdaq: PANC) ("Panacos" or "the Company"), a
biotechnology company dedicated to developing the next generation of antiviral
therapeutic products, has been invited to speak at the Bear Stearns Annual
Healthcare Conference, to be held at The Grand Hyatt Hotel in New York City on
Monday, September 12, 2005. Panacos' presentation is scheduled to begin that
day at 8:00 a.m., Eastern Daylight Time. Dr. Samuel K. Ackerman, President
and CEO of Panacos, will present.
A link to the live webcast of Panacos' presentation will be available on
the Company's Web site at http://www.panacos.com. The webcast link to access
a replay of the presentation will be archived and available through Monday,
September 19, 2005.
About Panacos Pharmaceuticals
Panacos, formerly known as V. I. Technologies, Inc. or VITEX, is
developing the next generation of anti-infective products through discovery
and development of small molecule oral drugs for the treatment of HIV and
other major human viral diseases. Panacos' proprietary discovery technologies
and lead therapeutic candidate PA-457 focus on novel targets in the virus life
cycle, including virus fusion and virus maturation. For more information on
Panacos, please visit our web site at: http://www.panacos.com.
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as the progress of clinical
development of PA-457, including the Company's plan to initiate a Phase 2b
study in the first half of 2006, and the timing of results of clinical trials,
the execution of the Company's financing plans, the potential role of PA-457
in treatment of HIV patients, the timely availability of new products, market
acceptance of the Company's products, the impacts of competitive products and
pricing, government regulation of the Company's products, the Company's
ability to complete product development collaborations and other strategic
transactions and other risks and uncertainties set forth in the Company's
filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any
forward-looking statements made herein.
CONTACT:
Peyton Marshall
Executive Vice President & CFO
617-926-1551
pmarshall@panacos.com
SOURCE Panacos Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panacos.com
CONTACT:
Peyton Marshall, Executive Vice President &
CFO of Panacos Pharmaceuticals, Inc., +1-617-926-1551,
pmarshall@panacos.com
|
